Status:
WITHDRAWN
Pharmacokinetic Study of Recombinant AT III in Neonates Undergoing ECMO
Lead Sponsor:
Children's Hospital Los Angeles
Conditions:
Neonates on ECMO
Eligibility:
All Genders
1-30 years
Phase:
PHASE4
Brief Summary
Maintenance of adequate anticoagulation or blood thinning is of critical importance when patients are placed on extracorporeal life support, such as extracorporeal membrane oxygenation (ECMO). During ...
Detailed Description
Maintenance of adequate anticoagulation is of critical importance when patients are placed on extracorporeal life support, such as ECMO. During ECMO, a patient's entire blood volume is constantly expo...
Eligibility Criteria
Inclusion
- Neonates requiring ECMO
- Must be \< or = to 30 days of age
- Must be \> or = to 37weeks corrected gestational age
Exclusion
- Older than or = to 31 days of age
- Preterm neonates \< 37weeks corrected gestational age
- Previously diagnosed hereditary coagulopathy or hemorrhagic disorder in the family
- Prior to recent anticoagulation use
- Known or suspected genetic or terminal disorder
- Known family history of hypersensitivity to goat's milk or goat milk products
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2014
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01913444
Start Date
July 1 2013
End Date
October 1 2014
Last Update
January 13 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027